Annual Total Liabilities
$1.33 B
-$559.10 M-29.58%
December 31, 2024
Summary
- As of February 26, 2025, BMRN annual total liabilities is $1.33 billion, with the most recent change of -$559.10 million (-29.58%) on December 31, 2024.
- During the last 3 years, BMRN annual total liabilities has fallen by -$408.15 million (-23.47%).
- BMRN annual total liabilities is now -29.58% below its all-time high of $1.89 billion, reached on December 31, 2023.
Performance
BMRN Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$1.33 B
-$106.85 M-7.43%
December 31, 2024
Summary
- As of February 26, 2025, BMRN quarterly total liabilities is $1.33 billion, with the most recent change of -$106.85 million (-7.43%) on December 31, 2024.
- Over the past year, BMRN quarterly total liabilities has dropped by -$106.85 million (-7.43%).
- BMRN quarterly total liabilities is now -36.75% below its all-time high of $2.10 billion, reached on September 30, 2020.
Performance
BMRN Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
BMRN Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -29.6% | -7.4% |
| 3 y3 years | -23.5% | -25.0% |
| 5 y5 years | -15.1% | -25.0% |
BMRN Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.6% | at low | -29.6% | at low |
| 5 y | 5-year | -29.6% | at low | -36.8% | at low |
| alltime | all time | -29.6% | >+9999.0% | -36.8% | >+9999.0% |
BioMarin Pharmaceutical Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $1.33 B(-29.6%) | $1.33 B(-7.4%) |
| Sep 2024 | - | $1.44 B(-19.3%) |
| Jun 2024 | - | $1.78 B(-1.0%) |
| Mar 2024 | - | $1.80 B(-4.8%) |
| Dec 2023 | $1.89 B(+6.7%) | $1.89 B(+1.5%) |
| Sep 2023 | - | $1.86 B(+4.5%) |
| Jun 2023 | - | $1.78 B(+0.3%) |
| Mar 2023 | - | $1.77 B(+0.2%) |
| Dec 2022 | $1.77 B(+1.9%) | $1.77 B(+4.5%) |
| Sep 2022 | - | $1.70 B(+3.3%) |
| Jun 2022 | - | $1.64 B(-1.8%) |
| Mar 2022 | - | $1.67 B(-3.9%) |
| Dec 2021 | $1.74 B(-0.2%) | $1.74 B(+1.6%) |
| Sep 2021 | - | $1.71 B(+3.3%) |
| Jun 2021 | - | $1.66 B(+0.8%) |
| Mar 2021 | - | $1.64 B(-5.7%) |
| Dec 2020 | $1.74 B(+11.1%) | $1.74 B(-17.2%) |
| Sep 2020 | - | $2.10 B(+1.9%) |
| Jun 2020 | - | $2.07 B(+39.3%) |
| Mar 2020 | - | $1.48 B(-5.4%) |
| Dec 2019 | $1.57 B(+7.4%) | $1.57 B(+5.7%) |
| Sep 2019 | - | $1.48 B(+3.6%) |
| Jun 2019 | - | $1.43 B(-4.4%) |
| Mar 2019 | - | $1.50 B(+2.7%) |
| Dec 2018 | $1.46 B(-20.0%) | $1.46 B(-18.0%) |
| Sep 2018 | - | $1.78 B(+2.3%) |
| Jun 2018 | - | $1.74 B(-2.8%) |
| Mar 2018 | - | $1.79 B(-1.9%) |
| Dec 2017 | $1.82 B(+45.1%) | $1.82 B(+3.2%) |
| Sep 2017 | - | $1.77 B(+44.3%) |
| Jun 2017 | - | $1.22 B(+4.7%) |
| Mar 2017 | - | $1.17 B(-7.0%) |
| Dec 2016 | $1.26 B(-5.4%) | $1.26 B(+5.1%) |
| Sep 2016 | - | $1.20 B(+2.3%) |
| Jun 2016 | - | $1.17 B(-15.0%) |
| Mar 2016 | - | $1.38 B(+3.6%) |
| Dec 2015 | $1.33 B(+40.2%) | $1.33 B(-0.3%) |
| Sep 2015 | - | $1.33 B(+3.1%) |
| Jun 2015 | - | $1.29 B(+4.7%) |
| Mar 2015 | - | $1.23 B(+30.2%) |
| Dec 2014 | $947.49 M(+4.9%) | $947.49 M(+1.7%) |
| Sep 2014 | - | $931.99 M(+5.5%) |
| Jun 2014 | - | $883.72 M(+0.4%) |
| Mar 2014 | - | $880.61 M(-2.5%) |
| Dec 2013 | $903.02 M(+63.4%) | $903.02 M(+162.5%) |
| Sep 2013 | - | $344.04 M(+0.2%) |
| Jun 2013 | - | $343.26 M(-1.4%) |
| Mar 2013 | - | $348.14 M(-37.0%) |
| Dec 2012 | $552.58 M(+3.7%) | $552.58 M(+0.1%) |
| Sep 2012 | - | $552.18 M(+3.8%) |
| Jun 2012 | - | $532.10 M(+1.3%) |
| Mar 2012 | - | $525.13 M(-1.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | $532.66 M(-2.3%) | $532.66 M(+2.3%) |
| Sep 2011 | - | $520.54 M(-5.0%) |
| Jun 2011 | - | $548.09 M(+0.9%) |
| Mar 2011 | - | $543.31 M(-0.4%) |
| Dec 2010 | $545.37 M(-8.3%) | $545.37 M(-17.2%) |
| Sep 2010 | - | $658.87 M(+5.8%) |
| Jun 2010 | - | $622.55 M(+0.3%) |
| Mar 2010 | - | $620.97 M(+4.4%) |
| Dec 2009 | $594.98 M(-5.6%) | $594.98 M(+5.2%) |
| Sep 2009 | - | $565.50 M(+0.8%) |
| Jun 2009 | - | $561.00 M(-10.4%) |
| Mar 2009 | - | $626.34 M(-0.6%) |
| Dec 2008 | $630.02 M(+0.4%) | $630.02 M(+1.4%) |
| Sep 2008 | - | $621.14 M(-1.2%) |
| Jun 2008 | - | $628.53 M(+1.6%) |
| Mar 2008 | - | $618.54 M(-1.4%) |
| Dec 2007 | $627.55 M(+81.6%) | $627.55 M(+1.8%) |
| Sep 2007 | - | $616.51 M(+0.4%) |
| Jun 2007 | - | $614.04 M(+115.4%) |
| Mar 2007 | - | $285.05 M(-17.5%) |
| Dec 2006 | $345.63 M(+26.7%) | $345.63 M(+0.2%) |
| Sep 2006 | - | $344.95 M(-17.8%) |
| Jun 2006 | - | $419.83 M(-5.1%) |
| Mar 2006 | - | $442.22 M(+62.1%) |
| Dec 2005 | $272.76 M(-9.4%) | $272.76 M(-0.5%) |
| Sep 2005 | - | $274.22 M(-1.2%) |
| Jun 2005 | - | $277.69 M(+2.4%) |
| Mar 2005 | - | $271.17 M(-9.9%) |
| Dec 2004 | $300.94 M(+117.3%) | $300.94 M(+1.0%) |
| Sep 2004 | - | $298.07 M(-2.0%) |
| Jun 2004 | - | $304.23 M(+116.5%) |
| Mar 2004 | - | $140.52 M(+1.5%) |
| Dec 2003 | $138.49 M(+1047.1%) | $138.49 M(-2.8%) |
| Sep 2003 | - | $142.48 M(-1.0%) |
| Jun 2003 | - | $143.95 M(+736.2%) |
| Mar 2003 | - | $17.21 M(+42.6%) |
| Dec 2002 | $12.07 M(-1.5%) | $12.07 M(+7.2%) |
| Sep 2002 | - | $11.26 M(+0.6%) |
| Jun 2002 | - | $11.19 M(-13.5%) |
| Mar 2002 | - | $12.94 M(+5.5%) |
| Dec 2001 | $12.26 M(+76.7%) | $12.26 M(+96.6%) |
| Sep 2001 | - | $6.24 M(+17.2%) |
| Jun 2001 | - | $5.32 M(+44.4%) |
| Mar 2001 | - | $3.68 M(-46.9%) |
| Dec 2000 | $6.94 M(+34.2%) | $6.94 M(+89.0%) |
| Sep 2000 | - | $3.67 M(+26.9%) |
| Jun 2000 | - | $2.89 M(-39.2%) |
| Mar 2000 | - | $4.76 M(-8.0%) |
| Dec 1999 | $5.17 M(+145.1%) | $5.17 M(-9.3%) |
| Sep 1999 | - | $5.70 M(-83.2%) |
| Jun 1999 | - | $34.00 M(+1900.0%) |
| Mar 1999 | - | $1.70 M |
| Dec 1998 | $2.11 M | - |
FAQ
- What is BioMarin Pharmaceutical annual total liabilities?
- What is the all time high annual total liabilities for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual total liabilities year-on-year change?
- What is BioMarin Pharmaceutical quarterly total liabilities?
- What is the all time high quarterly total liabilities for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly total liabilities year-on-year change?
What is BioMarin Pharmaceutical annual total liabilities?
The current annual total liabilities of BMRN is $1.33 B
What is the all time high annual total liabilities for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual total liabilities is $1.89 B
What is BioMarin Pharmaceutical annual total liabilities year-on-year change?
Over the past year, BMRN annual total liabilities has changed by -$559.10 M (-29.58%)
What is BioMarin Pharmaceutical quarterly total liabilities?
The current quarterly total liabilities of BMRN is $1.33 B
What is the all time high quarterly total liabilities for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly total liabilities is $2.10 B
What is BioMarin Pharmaceutical quarterly total liabilities year-on-year change?
Over the past year, BMRN quarterly total liabilities has changed by -$106.85 M (-7.43%)